1. Гаврилова Н.Е., Метельская В.А., Перова Н.В., Яровая Е.Б., Бойцов С.А., Взаимосвязь между выраженностью коронарного атеросклероза, факторами риска и маркерами атеросклеротического поражения каротидных и переферических артерий. //Кардиоваскулярная терапия и профилактика 2013, 12(1). с.40-45.

2. Alexander C.M., Landsman P.B., Teutsch S.M. et al. NCEF - defined metabolic syndrome, diabetes mellitus, and prevalens of coronary heart disease among NHANES III participants age 50 years and older// Diabetes - 2003. - Vol.52. P. 1210-1214.

3. Assmann G., Cullen P., Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study // Circulation. - 2002. - V.105. - p. 310-315.)

4. DECODE Study Group. Does diagnosis of the metabolic syndrome detect further men at high risk of cardiovascular death beyond those identified by a conventional cardiovascular risk score? The DECODE Study. //Eur J Cardiovasc Prev Rehabil. 2007;14(2):192-199.

5. БубноваМ.Г. Рольожиренияи висцерального жира в запуске сердечно-сосудистого континуума. Клинические эффекты орлистата. // Русский Медицинский Журнал 2014, №2. С. 116-123.

6. Garcia-Diaz D., Campion J., Milagro FI et al. Adiposity dependent apelin gene expression: relationships with oxidative and inflammation markers. // Mol Cell Biochem. 2007; 305: р. 87-94.

7. Leeper N. J., Tedesco M. M., Kojima Y. et al. Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation // Am. J. Physiol. Heart. Circ. Physiol. - 2009. Vol. 296. - P. 1329-1335.

8. Kleinz M. J., Davenport A. P. Emerging roles of apelin in biology and medicine // Pharmacology and Therapeutics. - 2005. - Vol. 107. - P. 198-211.

9. Шварц В. Адипонектин: патофизиологические аспекты //Патологическая физиология и экспериментальная терапия. - 2009. - №3. - С.34-38.

10. Koh, K.K., Quon M.J., Lee S.J. et al. Efonidipine simultaneously improves blood pressure, endothelial function, and metabolic parameters in non-diabetic patients with hypertension. // Diabetes Care. 2007. - Vol.30. - P. 1605-1607.

11. Васюк Ю.В., Садулаева И.А., Ющук Е.Н. Метаболический синдром: новые аспекты старой проблемы // Артериальная гипертензия. - 2007. - Том 13. - № 2. - С. 113-118.)

12. Рекомендации экспертов всероссийского научного общества кардиологов по диагностике и лечению метаболического синдрома. Второй пересмотр. Москва 2009.

13. Fox C,S., Massaro J.M., Hoffmann U. et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart study // Circulation. - 2007. - Vol. 116, № 1. - Р. 39-48.

14. Lear S.A., Humphries K.H., Kohli S. et al. Visceral adipose tissue, a potential risk factor for carotid atherosclerosis: results of the Multicultural Community Health Assessment Trial (M-CHAT) / // Stroke. - 2007. - Vol. 38, № 9. - P. 2422-2429.

15. Kramer C.K., D. Muhlen D., Gross J.L. et al. A prospective study of abdominal obesity and coronary artery calcium progression in older adults // J. Clin. Endocrinol. Metab. - 2009. - Vol. 94, № 12. - P. 5039-5044.

16. Kuk J.L., Katzmarzyk P.T., Nichaman M.Z. et al. Visceral fat is an independent predictor of all-cause mortality in men. //Obesity (Silver Spring). - 2006. - Vol. 14 № 2. - P. 336-341.

17. Koning L., Merchant A.T., Pogue J. et al. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies / // Eur. Heart. J. - 2007. - Vol. 28, № 7. - P. 850-856.

18. Hulthe J, Bokemark L, Wikstrand J, Fagerberg B. The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study. //Arterioscler Thromb Vasc Biol. 2000 Sep;20(9):2140-2147.

19. Rana J.S., Sondermeijer B.M., Arsenault B.J. et al. Non-high-density lipoprotein cholesterol levels vs apoliprotein B or Apo B/Apo A1 and risk of coronary heart disease among apparently healthy men and women // Circulation. - 2011. - Vol. 124. - P. A138-146.

20. Barter P. J., Ballantyne C.M., Carmena R. et al. Apo-B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ ten-country panel // J. Intern. Med. - 2006. - Vol. 259, № 3. - P. 247-258.

21. Boucher J., Masri B., Daviaud D. et al. Apelin, a newly identified adipokine upregulated by insulin and obesity. //Endocrinology 2005. Vol.146. №4. P1764-1771.

22. Rowyda Nawwaf Al-Harithy. Serum Apelin-12 Concentration in Saudi Obese Middle-Aged Men. // Life Science Journal 2014;11(10). P.1113-1117.

23. Tapan S., Tascilar E., Abaci A. et al. Decreased plasma apelin levels in pubertal obese children. //J PediatrEndocrinol Metab. 2010. Vol.23. №10. P.1039-1046.

24. Zhou Y, Wang Y, Qiao S.Apelin: a potential marker of coronary artery stenosis and atherosclerotic plaque stability in ACS patients.//Int Heart J. 2014;55(3):204-212.

25. Аронов Д.М., Лупанов В.П. Некоторые аспекты патогенеза атеросклероза.// Атеросклероз и дислипидемии. 2011. № 1. C. 48-56.

26. Abu-Amero K.K., Al-Boudari O.M., Mohamed G.H., Dzimiri N. E-selectin S128R polymorphism and severe coronary artery disease in Arabs. // BMC Medical Genetics. 2006 Jun 6;7:52. doi:10.1186/1471- 2350-7-52.

27. Zanni MV, Stanley TL, Makimura H, Chen CY, Grinspoon SK. Effects of TNF-alpha antagonism on E-selectin in obese subjects with metabolic dysregulation.//Clin Endocrinol (Oxf).2010 Jul;73(1):48-54.

28. Choi KM, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH. Serumadiponectin, interleukin-10 levelsand inflammatory markers in the metabolic syndrome. Diabetes Res Clin Pract. 2007;75(2):235-240.

29. Jacobs M, van Greevenbroek MM, van der Kallen CJ, Ferreira I, Blaak EE, Feskens EJ, Jansen EH, Schalkwijk CG, Stehouwer CD. Low-grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: the CODAM study. Eur J Clin Invest. 2009;39(6):437-444.